. 2015 Dec 30;7:119. doi: 10.1186/s13098-015-0115-3

Table 3.

Comparison of nephropathy development and laboratory data in patients with type 2 DM

	With nephropathy (n =29)	Without nephropathy (n = 41)	Controls (n =31)	p
MPO (%)	80 (70–85)	75 (54–88)	88 (78–92)^a	0.003^b
HBA1C (%)	9 (7.1–12)	6.9 (6.15–10.8)	5.4 (5–5.5)^a	<0.001^b
Sedimentation (mm/h)	38 ± 21.25	40.39 ± 20.63	26.48 ± 16.45^c	0.011^d
C-reactive protein (g/dl)	3.44 (1.5–7.93)	2.41 (0.99–4.1)	1.38 (0.94–3.63)^e	0.024^b

^aControl group is different from other groups

^bIt was used the Kruskal–Wallis test for statistical analysis

^cControl group and the group without nephropathy are different from each other

^dIt was used the ANOVA test for statistical analysis

^eControl group and the group with nephropathy are different from each other